- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02635230
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2. (WOEST 2)
An International Prospective Registry on Concomitant Use of Oral Anticoagulants and P2Y12 Inhibitors in Patients With Atrial Fibrillation or Heart Valve Prosthesis Undergoing Coronary Revascularisation.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with stenting, is still unknown. For these patients current North American and European guidelines recommend a triple therapy strategy, including vitamin K antagonists (VKA), aspirin and clopidogrel. A major drawback of this triple therapy strategy is a significant increase in the risk of major bleeding. Furthermore, the ommitance of aspirin and the introduction of more potent P2Y12 inhibitors as well as the non-vitamin K oral anticoagulants (NOAC), created numerous new antithrombotic treatment strategies for these patients with overlapping conditions. To date, evidence on the risks and benefits of these new antithrombotic treatment strategies is lacking.
The WOEST 2 Registry aims to improve medical care for patients with AF and/or a heart valve prosthesis ánd undergoing coronary revascularisation through a better understanding of their demographics, antithrombotic management and related in-hospital and long-term outcomes. The WOEST 2 Registry will provide data to support benchmarking of antithrombotic treatment patterns and patient outcomes.
Objective: To assess the different management patterns and related in-hospital and long-term safety and efficacy outcomes of combined use of chronic oral anticoagulation and a P2Y12 inhibitor in patients with atrial fibrillation and/or a heart valve prosthesis undergoing coronary revascularisation.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The WOEST 2 Registry is a prospective, international, multi-centre, non-interventional, cohort study designed to recruit an unselected cohort of patients with atrial fibrillation and/or a heart valve prosthesis undergoing coronary revascularisation.
Trial overview
Name : WOEST 2 REGISTRY
Target for enrollment : 2200 patients
Time frame for inclusion : within 72 hours after index PCI or coronary artery bypass grafting (CABG)
Follow-up : 24 months
Visits : 30 days, 12 and 24 months after index PCI or CABG
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
-
Aalst, Belgien
- Aktiv, inte rekryterande
- Onze Lieve Vrouw Ziekenhuis
-
Antwerpen, Belgien
- Aktiv, inte rekryterande
- Universitair Ziekenhuis Antwerpen
-
Bonheiden, Belgien
- Rekrytering
- Imelda Ziekenhuis
-
Genk, Belgien
- Rekrytering
- Ziekenhuis Oost-Limburg
-
Leuven, Belgien
- Aktiv, inte rekryterande
- Universitair Ziekenhuis Leuven
-
-
-
-
-
Amsterdam, Nederländerna
- Aktiv, inte rekryterande
- Onze Lieve Vrouwe Gasthuis
-
Breda, Nederländerna
- Aktiv, inte rekryterande
- Amphia Ziekenhuis
-
Nieuwegein, Nederländerna
- Rekrytering
- St. Antonius Hospital
-
Kontakt:
- Wilbert Bor, MD
- Telefonnummer: +31640907188
- E-post: w.bor@antoniusziekenhuis.nl
-
Tilburg, Nederländerna
- Aktiv, inte rekryterande
- Elizabeth-Tweesteden Ziekenhuis
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
In order to be eligible to be included in this registry, a subject must meet ALL of the following criteria:
- Patient is ≥ 18 years of age;
- Patients with a diagnosis of atrial fibrillation (prior to hospitalisation ór during hospitalisation within 72h after coronary revascularisation) and/or with a heart valve prosthesis (aortic/mitral);
- Chronic treatment with OAC or NOAC therapy at inclusion or the intention to start chronic treatment with OAC or NOAC within 72h after coronary revascularisation AND with intended duration of treatment for at least one year after inclusion in the registry;
- Indication for coronary revascularisation by CABG or PCI (with deployment of at least 1 coronary stent);
- Prescription of a P2Y12 inhibitor (clopidogrel, ticagrelor or prasugrel) because of CABG following acute coronary syndrome* and /or because of PCI (with deployment of at least 1 coronary stent).
- Patient has provided written informed consent.
Exclusion Criteria:
A potential subject who meets ANY of the following criteria will be excluded from participation in this study:
- Patients unable to sign informed consent (including mental disabled patients);
- Patients with life expectancy < 1 year;
- Allergy or intolerance to P2Y12 inhibitors.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Patients with chronic oral anticoagulation and P2Y12 inhibitor
Patients with chronic indication for chronic oral anticoagulation (OAC) because of a heart valve prosthesis and/or atrial fibrillation undergoing coronary revascularisation (by PCI or CABG) and requiring concomitant treatment with P2Y12 inhibitors.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Composite of the rate of non-fatal myocardial infarction, non-fatal ischemic stroke (including transient ischemic attack), non-central nervous system systemic embolization and cardiovascular death [the primary efficacy outcome].
Tidsram: 1 year
|
1 year
|
|
|
The occurrence of any bleeding episode requiring in-hospital medical attention and/or a switch of antithrombotic medication [the primary safety outcome].
Tidsram: 1 year
|
Bleeding will be classified by the Bleeding Academic Research Consortium (BARC) 2, 3, 4 and 5 bleeding criteria and by the Thrombolysis in Myocardial Infarction (TIMI) minor and major bleeding criteria.
|
1 year
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Jurriën M ten Berg, MD, PhD, St. Antonius Hospital Nieuwegein, the Netherlands
- Huvudutredare: Willem JM Dewilde, MD, PhD, Imelda Hospital Bonheiden, Belgium
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- Ticagrelor
- Aspirin
- Rivaroxaban
- Hjärt-kärlsjukdomar
- Prasugrel
- Trombos
- Warfarin
- Blödning
- Hjärtinfarkt
- Trombocytaggregationshämmare
- Clopidogrel
- Apixaban
- Ischemisk stroke
- Hjärtsjukdom
- Oral antikoagulering
- Myokardischemi
- Atrial Fibrillations
- Koronarartärbypasstransplantation
- Embolism och trombos
- Akuta kranskärlssyndrom
- Kranskärlssjukdomar
- Antitrombotisk behandling
- Perkutan koronar revaskularisering
- Heart Valve Prostheses
- Dabigatran etexilate mesylate
- Direct Factor Xa Inhibitors
- Direct Thrombin Inhibitors
Ytterligare relevanta MeSH-villkor
- Ischemi
- Patologiska processer
- Nekros
- Hjärtsjukdom
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Arterioskleros
- Arteriella ocklusiva sjukdomar
- Arytmier, hjärt
- Hjärtinfarkt
- Infarkt
- Kranskärlssjukdom
- Myokardischemi
- Kranskärlssjukdom
- Förmaksflimmer
- Blödning
- Akut koronarsyndrom
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Agenter från det perifera nervsystemet
- Enzyminhibitorer
- Analgetika
- Sensoriska systemagenter
- Antiinflammatoriska medel, icke-steroida
- Analgetika, icke-narkotiska
- Antiinflammatoriska medel
- Antireumatiska medel
- Fibrinolytiska medel
- Fibrinmodulerande medel
- Trombocytaggregationshämmare
- Cyklooxygenashämmare
- Antipyretika
- Aspirin
Andra studie-ID-nummer
- R&D/Z14.016/WOEST2
- WOEST2-004 (Annan identifierare: WOEST 2 Study Team)
- V.21483/W14.007 (Annan identifierare: Medical research Ethics Committees United - St. Antonius Hospital, the Netherlands)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .